Works matching IS 11732563 AND DT 2022 AND VI 42 AND IP 4

Results: 9

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 333, doi. 10.1007/s40261-022-01138-6

By:

Michaeli, Daniel Tobias;
Stoycheva, Sophia;
Marcus, Simon Mashudu;
Zhang, Wenjia;
Michaeli, Julia Caroline;
Michaeli, Thomas

Publication type:

Article

Comparison of Warfarin Initiation at 3 mg Versus 5 mg for Anticoagulation of Patients with Mechanical Mitral Valve Replacement Surgery: A Prospective Randomized Trial.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 309, doi. 10.1007/s40261-022-01137-7

By:

Sabry, Sarah;
El Wakeel, Lamia Mohamed;
Saleh, Ayman;
Ahmed, Marwa Adel

Publication type:

Article

Tralokinumab in Atopic Dermatitis: A Profile of Its Use.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 365, doi. 10.1007/s40261-022-01135-9

By:

Blair, Hannah A.

Publication type:

Article

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [<sup>14</sup>C]‑BI 425809 in Healthy Males.

Published in:

2022

By:

Burkard, Ute;
Desch, Michael;
Shatillo, Yury;
Wunderlich, Glen;
Mack, Salome Rebecca;
Schlecker, Christina;
Teitelbaum, Aaron M.;
Liu, Pingrong;
Chan, Tom S.

Publication type:

Correction Notice

Multiple Sclerosis Relapses Following Cessation of Fingolimod.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 355, doi. 10.1007/s40261-022-01129-7

By:

Malpas, Charles B.;
Roos, Izanne;
Sharmin, Sifat;
Buzzard, Katherine;
Skibina, Olga;
Butzkueven, Helmut;
Kappos, Ludwig;
Patti, Francesco;
Alroughani, Raed;
Horakova, Dana;
Havrdova, Eva Kubala;
Izquierdo, Guillermo;
Eichau, Sara;
Hodgkinson, Suzanne;
Grammond, Pierre;
Lechner-Scott, Jeannette;
Kalincik, Tomas

Publication type:

Article

A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 285, doi. 10.1007/s40261-022-01133-x

By:

Choi, Dasom;
Lee, Soohyun;
Kim, Seungmin;
Yoon, Sangwook

Publication type:

Article

Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 301, doi. 10.1007/s40261-022-01130-0

By:

Singh, Alok;
Balasundaram, Mahesh Kumar

Publication type:

Article

Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 345, doi. 10.1007/s40261-022-01128-8

By:

Ruggeri, Matteo;
Signorini, Alessandro;
Caravaggio, Silvia;
Rua, João;
Luís, Nuno;
Braz, Sandra;
Aragão, Filipa

Publication type:

Article

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 4, p. 319, doi. 10.1007/s40261-022-01120-2

By:

Rivero-Ferrer, Elena;
Olesen, Morten;
Plana, Estel;
Aguado, Jaume;
Saigí-Morgui, Núria;
Rubino, Annalisa;
Daoud, Sami Z.;
Lei, Alejhandra;
Perez-Gutthann, Susana;
Schink, Tania;
Kristiansen, Nina Sahlertz;
Hallas, Jesper;
Pottegård, Anton;
Rebordosa, Cristina

Publication type:

Article